LIVER
Adiponectin and its receptors in non-alcoholic
steatohepatitis
S Kaser, A Moschen, A Cayon, A Kaser, J Crespo, F Pons-Romero, C F Ebenbichler, J R Patsch,
H Tilg
...............................................................................................................................
See end of article for
authorsâ€™ affiliations
.......................
Correspondence to:
Dr H Tilg, University
Hospital Innsbruck,
Department of Medicine,
Division of
Gastroenterology and
Hepatology, Anichstrasse
35, 6020 Innsbruck,
Austria; herbert.tilg@
uibk.ac.at
Revised version received
31 May 2004
Accepted for publication
13 June 2004
.......................
Gut 2005;54:117â€“121. doi: 10.1136/gut.2003.037010
Background: Adiponectin, an adipocyte derived polypeptide, has been shown to alleviate steatosis and
inflammation in mice with non-alcoholic fatty liver disease.
Aim: In the present study, we wished to define liver expression of adiponectin and its receptors in morbidly
obese patients undergoing bariatric surgery. Patients with non-alcoholic steatohepatitis (NASH) or simple
steatosis were investigated to test whether dysregulation of this system might be involved in these disorders.
Patients and methods: Liver mRNA expression of adiponectin and its recently cloned receptors RI and RII
(adipoRI and adipoRII) were analysed by fluorescence based real time polymerase chain reaction in 13
patients with NASH and nine with simple steatosis. Adiponectin and adipoRII protein expression were
assessed by immunohistochemistry in a subgroup of patients.
Results: Adiponectin and adipoRII mRNA expression were significantly reduced in liver biopsies of patients
with NASH compared with simple steatosis while no difference was found in adipoRI mRNA expression. In
NASH, adipoRII mRNA expression was negatively correlated with serum aspartate aminotransferase
levels, serum alanine aminotransferase levels, and grade of fibrosis. Liver adiponectin protein expression
was mainly found in endothelial cells of portal vessels and liver sinusoids whereas adipoRII expression was
seen in hepatocytes only. Adiponectin and adipoRII staining were lower in biopsies of subjects with NASH
compared with simple steatosis.
Conclusion: Reduced hepatic expression of adiponectin and adipoRII might be of pathophysiological
relevance in non-alcoholic fatty liver diseases.
Non-alcoholic steatohepatitis (NASH) is frequently
associated with abdominal obesity, hypertension,
and diabetes. Insulin resistance has been implicated
as a key mechanism in the pathogenesis of NASH. Numerous
substances, mainly released by adipocytes, are thought to
contribute to peripheral insulin resistance. These include
proinflammatory cytokines such as interleukin (IL)-6 and
tumour necrosis factor a (TNF-a) as well as leptin, resistin,
and also acrp30/adiponectin/adipoQ.1 2 Adiponectin is an
antidiabetic and antiatherogenic acting polypeptide that is
strongly correlated with systemic insulin sensitivity in
humans.134 Adiponectin increases fatty acid beta oxidation
in muscle,5 improves postabsorptive insulin mediated supï¿¾pression of hepatic glucose output by enhancing hepatic
insulin action,6 and decreases lipid accumulation in macroï¿¾phages.7 Beyond its metabolic effects, adiponectin also has
direct anti-inflammatory effects.8
Xu et al reported that adiponectin administration alleviates
non-alcoholic fatty liver disease in mice. In detail, adminisï¿¾tration of adiponectin improved hepatomegaly and steatosis,
attenuated inflammation, and elevated levels of serum
alanine aminotransferase in ob/ob mice.9
Recently, cloning of adiponectin receptors I and II (adipoRI
and adipoRII) was reported.10 While in mice adipoRI is
abundantly expressed in skeletal muscle, adipoRII is preï¿¾dominantly expressed in the liver. AdipoRI and adipoRII
mediate increased AMP kinase and peroxisome proliferator
activated receptor (PPAR)-a ligand activities, fatty acid
oxidation, and glucose uptake by adiponectin, respectively.
Based on these functional characteristics of the adiponecï¿¾tin/adipoRI/adipoRII system, we hypothesised that dysreguï¿¾lation of this system could contribute to the development of
NASH in obese subjects. We therefore determined liver
expression of adiponectin and its receptors in morbidly obese
patients undergoing elective bariatric surgery and compared
patients with NASH with those with simple steatosis.
METHODS
Study design
Twenty two patients with a diagnosis of obesity undergoing
bariatric surgery by performing a biliopancreatic diversion
consisting of a partial gastrectomy with a distal Roux-en-Y
reconstruction participated in this study. Subjects with a
history of excessive drinking or other liver diseases, including
alcoholic liver disease, viral hepatitis, autoimmune hepatitis,
primary biliary cirrhosis, haemochromatosis, Wilsonâ€™s disï¿¾ease, or a1 antitrypsin deficiency were excluded from the
study. In 13 patients, NASH was defined as a clinical and
pathological entity characterised by the presence of steatosis
as well as lobular and/or portal inflammation with or without
fibrosis11; in nine patients histologically confirmed simple
steatosis was diagnosed. Liver fibrosis (scale 0â€“4) and
steatosis (grade 0â€“3) were assessed semiquantitatively and
necroinflammatory activity was determined as described
recently.11 None of the patients had signs of hepatic
complications, heart failure, organic renal disease, associated
autoimmune conditions, cancer, or any other severe illness.
Informed written consent was obtained from all subjects.
Abbreviations: NASH, non-alcoholic steatohepatitis; adipoRI,
adiponectin receptor I; adipoRII, adiponectin receptor II; AST, aspartate
aminotransferase; ALT, alanine aminotransferase; c-GT, gamma
glutamyl transferase; IL, interleukin; TNF, tumour necrosis factor;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PPAR,
peroxisome proliferator activated receptor; HOMA, homeostasis model
assessment
117
www.gutjnl.com
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. 
. Technical Services Serials
at New York University, Serials Bobst Library on November 3, 2025 http://gut.bmj.com/ Downloaded from 10 December 2004. 10.1136/gut.2003.037010 on Gut: first published as 

Laboratory measurements
Venous blood was drawn after an overnight fast and plasma
or serum was obtained by centrifugation at 3000 rpm for
10 minutes at 4ËšC immediately after blood collection. Plasma
and serum samples were either used immediately for analysis
or were stored frozen at 280ËšC.
Insulin sensitivity was estimated by the homeostasis model
assessment (HOMA) index.12 Aspartate aminotransferase
(AST), alanine aminotransferase (ALT), gamma glutamyl
transferase (c-GT), insulin, and glucose concentrations were
measured using commercially available enzymatic kits.
Serum adiponectin concentrations were determined using
a commercially available radioimmunoassay kit (Linco
Research Inc, St Charles, Missouri, USA).
RNA isolation
Liver biopsies were collected by Tru-cut from each subject.
Total RNA was extracted from frozen liver by the acid
guanidinium phenol chloroform method using Trizol reagent
(Gibco, Gaithersburg, Maryland, USA). Extracted RNA was
quantified by spectrophotometry. Reverse transcription of
1 mg of RNA was performed using the Omniscript RT Kit
(Qiagen, Hilden, Germany).
Fluorescence based real time polymerase chain
reaction
mRNA of adipoRI, adipoRII, and adiponectin were estimated
by quantification of adipoRI, adipoRII, adiponectin, and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA
by the TaqMan real time polymerase chain reaction (PCR)
(Perkin Elmer, Vienna, Austria) method expressed as
adipoRI/GAPDH cDNA ratio, adipoRII/GAPDH cDNA ratio,
and adiponectin/GAPDH cDNA ratio, respectively.
For generation of the standard curve, serially diluted cDNA
prepared from human HepG2 cells (adipoRI, adipoRII) and
human SGBS cells (adiponectin) were used. Briefly, 2.5 ml of
each reverse transcription served as template in a 25 ml PCR
containing 12.5 ml Taq Man Universal Polymerase Master
Mix (Applied Biosystems, Foster City, California, USA),
2.25 ml (10 pmol/ml) of each oligonucleotide primer (MWG
Ebersberg, Germany), 0.5 ml of Taq Man probe (10 nmol/ml)
(Microsynth, Baglach, Switzerland), and 5 ml aqua dest.
TaqMan probes were labelled with the reporter fluorescent
dye 6-carboxyfluorescein (FAM) at the 59 end and with the
quencher 6-carboxy-tetramethyl-rhodamine (TAMRA) at the
39 end. AdipoRI, adipoRII, and adiponectin quantities were
normalised to the amount of GAPDH cDNA which was
determined using the GAPDH reaction mix. The PCR reaction
was performed in triplicate in MicroAmp 96 well reaction
plates (Perkin Elmer); amplification was carried out in
the AbiPrism 7700 Sequence Detector (Perkin Elmer).
Amplification conditions were two minutes at 50ËšC, 10 minï¿¾utes at 95ËšC, followed by 40 cycles of 15 seconds at 95ËšC, and
one minute at 60ËšC. Results were analysed using the
Sequence Detector 1.6 software.
Oligonucleotide primers and TaqMan probes were designed
using Primer express software (Perkin-Elmer Applied
Biosystems, Warrington, UK). Primers included: adipoRI:
forward: 59-ACT GAG AAG AGA AAA ACA AAA ATA AAT
CAT AC-39 and reverse: 59-GAA TAA GCC AGG GTT TGG GCï¿¾39; adipoRII: forward: 59-GCA CTA TGT CAT CTC GGA GGGï¿¾39 and reverse: 59-GCC ATC AGC ATC AAC CAG C-39;
adiponectin: forward: 59-AGA TGG CAC CCC TGG TGA G-39
and reverse: 59-GGG TAC TCC GGT TTC ACC G-39; TaqMan
Probes: adipoRI: 59-TCA AAG GAT GGA GTG CAT CAA TTG
GGA-39; adipoRII: 59-CTT AAG GCC GCC ACC ATA GGG CAG
ATA-39; and adiponectin: 59-AAA GGA GAT CCA GGT CTT
ATT GGT CCT AAG GGA-39.
Immunohistochemistry
Immunohistochemistry for adiponectin and adipoRII was
performed in liver biopsies in a subgroup of study subjects
(five patients with NASH and five with simple steatosis).
Polyclonal antibodies against human adiponectin and human
adipoRII were purchased from R&D Systems (McKinley
Place, Minnesota, USA) and Phoenix Pharmaceuticals
(Belmont, California, USA), respectively. Sections (4 mm)
were prepared from formalin fixed paraffin embedded tissue
specimens, deparaffinised, and rehydrated in graded alcoï¿¾hols. A heat induced epitope retrieval technique by autoclavï¿¾ing slides for several minutes in 10 mM citric acid buffer was
used for detection of adiponectin and its receptors. After
quenching endogenous peroxidase with 3% H2O2 in phosï¿¾phate buffered saline for 10 minutes, slides were incubated
with primary antibodies at 4ËšC overnight (antihuman
adiponectin pAb, 1 mg/ml; antihuman adipoRII pAb,
3 mg/ml). Specificity for adiponectin was demonstrated by
blocking the primary antibody with recombinant human
adiponectin (R&D Systems) at 4ËšC overnight. Solid phase
absorbed rabbit Ig fraction (DakoCytomation, Glostrup,
Denmark) was used to demonstrate specificity of adipoRII
pAb staining. Visualisation was performed using the LSAB+
kit (DakoCytomation) with 3, 39-diaminobenzidine as chroï¿¾mogen according to the manufacturerâ€™s instructions. Sections
Table 1 Anthropomorphic and clinical characteristics of
all study patients
NASH
(n = 13)
Controls
(n = 9) p Value
Age (y) 44 (3.1) 34 (4.3) NS
Sex (F/M) 9/4 7/2 NS
BMI (kg/m2
) 45.59 (1.37) 47.90 (2.69) NS
AST (U/l) 26.75 (4.26) 21.44 (1.86) NS
ALT (U/l) 41.17 (8.67) 23.44 (1.59) NS
c-GT (U/l) 49.83 (7.71) 27.62 (10.84) NS
HOMA index 2.32 (0.61) 2.34 (0.87) NS
Adiponectin (mg/ml) 5.38 (0.92) 6.86 (1.15) NS
Grade of steatosis (1â€“4) 1.46 (0.24) 1.22 (0.22) NS
Grade of fibrosis (1â€“4) 1.85 (0.25) 1.00 (0) ,0.01
Grade of inflammation (1â€“4) 1.92 (0.21) 1.00 (0) ,0.01
NASH, non-alcoholic steatohepatitis; BMI, body mass index; AST,
aspartate aminotransferase; ALT, alanine aminotransferase; c-GT,
gamma glutamyl transferase; HOMA, homeostasis model assessment.
Grade of steatosis, fibrosis, and inflammation were histologically verified
and classified as: grade 1, no; grade 2, light; grade 3, mild; and grade
4, severe.
Values are means (SEM).






	 
 	 
 	 


 
  
  	   
Figure 1 Adiponectin receptor I/glyceraldehyde-3-phosphate
dehydrogenase (adipoRI/GAPDH) cDNA ratio, adiponectin receptor II
(adipoRII)/GAPDH cDNA ratio, and adiponectin/GAPDH cDNA ratio in
liver biopsies of patients with non-alcoholic steatohepatitis (NASH) and
those with simple steatosis (controls). Values are means (SEM); p values
,0.05 were considered significant.
118 Kaser, Moschen, Cayon, et al
www.gutjnl.com
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. 
. Technical Services Serials
at New York University, Serials Bobst Library on November 3, 2025 http://gut.bmj.com/ Downloaded from 10 December 2004. 10.1136/gut.2003.037010 on Gut: first published as 

were counterstained with haematoxylin, dehydrated, and
mounted permanently in Eukitt (O Kindler GmbH, Freiburg,
Germany). Finally, sections were viewed on an Olympus
IX70 with Kappa camera and Kappa ImageBase 2.2 softï¿¾ware (Kappa opto-electronics GmbH, Gleichen, Germany).
Staining intensity was semiquantitatively assessed in a
blinded fashion by assigning an arbitrary value of 1, 2, or 3
(reflecting weak, intermediate, and bright staining) to each
specimen.
Statistical analysis
Differences between groups were calculated using the
Studentâ€™s t test for independent samples. Statistical signifiï¿¾cance was inferred at a two tailed p value of less than 0.05.
Correlation coefficients were calculated using Pearsonâ€™s
method. Descriptive data are expressed as mean (SEM).
SPSS for windows (version 11.0) was used for statistical
analysis.
RESULTS
Clinical characteristics
Clinical characteristics of study subjects are summarised in
table 1. Body mass index, AST, ALT, c-GT, and insulin
sensitivity estimated by the HOMA index were similar in
patients with NASH and simple steatosis. Serum adiponectin
levels measured by radioimmunoassy were similar in patients
with NASH (5.38 (0.92) mg/ml) and those with simple
steatosis (6.86 (1.15) mg/ml; p = 0.18).
Hepatic mRNA expression
While the adipoRI/GAPDH cDNA ratio tended to be lower in
liver biopsies of subjects with NASH without reaching
statistical significance (4.91 (0.62) v 6.71 (2.03); p = 0.08),
the adipoRII/GAPDH cDNA ratio was significantly decreased
in liver biopsies of patients with NASH compared with those
with simple steatosis (3.91 (0.35) v 7.96 (2.37); p = 0.04). The
adiponectin/GAPDH cDNA ratio was significantly lower in
liver biopsies of patients with NASH (0.15 (0.07)) compared
with those with simple steatosis (0.66 (0.62); p = 0.01).
AdipoRI/GAPDH, adipoRII/GAPDH, and adiponectin/GAPDH
cDNA ratios are shown in fig 1.
Liver TNF-a cDNA/b-actin cDNA ratio, as determined by
semiquantitative PCR analysis,11 was significantly higher in
patients with NASH compared with those with simple
steatosis (0.95 (0.16) v 0.22 (0.08); p,0.01) while liver
TNF-a receptor type I (p55) and TNF-a receptor type II (p75)
mRNA expression were similar in both groups.
Immunohistochemistry
Immunohistochemistry for adiponectin and adipoRII (fig 2)
was performed in liver biopsies in a subgroup of our study
patients (five with NASH and five with simple steatosis).
Adiponectin protein expression was localised primarily to
endothelial cells of portal vessels and liver sinusoids.
Adiponectin staining was less pronounced in endothelial
cells of liver sinusoids in patients with NASH (fig 2D, E)
compared with subjects with simple steatosis (fig 2Aâ€“C) (1.4
(0.24) v 2.25 (0.25); p = 0.05). AdipoRII protein was localised
to hepatocytes showing a predominantly cytoplasmic staining
pattern. AdipoRII staining again tended to be less proï¿¾nounced in liver biopsies of subjects with NASH (fig 2H)
compared with subjects with simple steatosis (fig 2G) (1.6
(0.25) v 2.25 (0.25); p = 0.11).
Correlations of adiponectin and its receptors with
other laboratory measurements
In subjects with NASH, adipoRII/GAPDH cDNA ratio was
negatively correlated with AST (r = 20.68, p = 0.02), ALT
Figure 2 Immunohistochemistry for adiponectin and adiponectin receptor II (adipoRII) in human liver specimens. (A, B, C) Expression and distribution
of adiponectin in simple steatosis (A 1006; B 2006; C 4006). (D, E) Staining for adiponectin in non-alcoholic steatohepatitis (NASH) (D 1006;
E 2006). Expression and distribution of adipoRII is shown in (G) (simple steatosis, 2006) and (H) (NASH, 2006). Negative controls were performed
by blocking adiponectin pAb with recombinant human adiponectin (F) and using a rabbit Ig fraction from non-immunised rabbits for adipoRII (I)
(both 2006). Representative experiments in liver biopsies from five patients with NASH and five with simple steatosis.
Adiponectin and its receptors in NASH 119
www.gutjnl.com
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. 
. Technical Services Serials
at New York University, Serials Bobst Library on November 3, 2025 http://gut.bmj.com/ Downloaded from 10 December 2004. 10.1136/gut.2003.037010 on Gut: first published as 

(r = 20.73, p = 0.01), and histological grade of fibrosis
(r = 20.58, p = 0.04). Hepatic adiponectin mRNA expression
was positively correlated with grade of steatosis in patients
with simple steatosis (r = 0.969, p = 0.03) while no correlaï¿¾tion was found between these parameters in subjects with
NASH. Adiponectin/GAPDH cDNA expression was signifiï¿¾cantly correlated with serum levels of c-GT (r = 0.86,
p = 0.01) and alkaline phosphatase (r = 0.62, p = 0.04) in
subjects with NASH. No correlations were observed with
these laboratory parameters in patients with simple steatosis.
No correlation was found between adipoRI/GAPDH cDNA
ratio and AST and ALT levels. Furthermore, there was no
correlation between serum adiponectin and hepatic adipoï¿¾nectin, adipoRI, or adipoRII mRNA expression in any group,
respectively.
When subjects with NASH and simple steatosis were
analysed together, hepatic adiponectin mRNA expression
was correlated with liver TNF-a receptor type I (p55)
mRNA expression (r = 0.51, p = 0.05) while no correlation
between these parameters was found when subjects with
NASH or simple steatosis were considered separately.
Furthermore, no correlation was identified between mRNA
expression of hepatic adiponectin or its receptors and liver
TNF-a/TNF-a receptor type II (p75) mRNA expression in any
group.
DISCUSSION
The aim of this study was to define a potential role of
adipocyte derived adiponectin and its receptors adipoRI and
adipoRII in the pathogenesis of NASH in patients with severe
obesity. Our results suggest that in NASH, local effects of
adiponectin are limited through two different mechanisms:
(i) decreased adiponectin mRNA expression and (ii)
decreased mRNA expression of hepatic adipoRII.
Furthermore, we observed a negative correlation between
adipoRII/GAPDH cDNA ratio and AST and ALT levels and
grade of fibrosis. Our immunohistochemistry data further
support the notion that adiponectin and adipoRII are
diminished in NASH.
In contrast with adipoRII, hepatic adipoRI mRNA expresï¿¾sion was similar in NASH and simple steatosis. While
adipoRII is predominantly expressed in the liver,10 adipoRI
is mainly expressed in skeletal muscle,10 13 suggesting that
in the liver the effects of adiponectin are predominï¿¾antly mediated by adipoRII. While adipoRI is a high
affinity receptor for globular adiponectin, adipoRII can
mediate binding of both globular and full length
adiponectin and thus can increase PPAR-a ligand activity
and fatty acid oxidation by globular and full length
adiponectin.10
Notably, adiponectin was mainly localised to endothelial
cells of portal vessels and liver sinusoids while adipoRII was
exclusively detected in hepatocytes. This may suggest that
this hormone/receptor pair could function in a paracrine way
in the liver and this interaction could be impaired in NASH.
Furthermore, we found no correlation between circulating
adiponectin levels and liver adiponectin expression. This
could suggest that liver adiponectin expression is regulated
by different factors, for example, proinflammatory cytokines
such as TNF-a.
Recently, it was reported that TNF-a and adiponectin
suppress each otherâ€™s production and are also able to
antagonise each otherâ€™s action.8 Therefore, reduced adipoï¿¾nectin mRNA expression might be partially due to these
suppressive effects of elevated TNF-a expression in NASH.11 14
In fact, we found increased liver TNF-a mRNA expression in
subjects with NASH. Lack of a negative correlation between
hepatic adiponectin mRNA expression and liver TNF-a
mRNA expression might simply be due to the small number
of subjects studied.
Decreased adiponectin liver activity may result in
decreased fatty oxidation, glucose uptake, and reduced
PPAR-a activity (which acts as the molecular target for lipid
lowering fibrates and is strongly involved in hepatic fatty acid
catabolism). Reduced effects of adiponectin on hepatic fatty
acid metabolism could contribute to the development of
steatohepatitis in patients with NASH. Our hypothesis is
supported by the findings of Xu and colleagues9 who
investigated the effects of adiponectin administration in ob/
ob mice. The authors reported enhanced hepatic fatty acid
oxidation and decreased acetyl-CoA carboxylase and fatty
acid synthase activitiesâ€”two key enzymes of fatty acid
synthesisâ€”after adiponectin delivery, resulting in reduced
steatosis.
Recently, long term treatment with the PPAR-c agonist
rosiglitazone improved not only insulin sensitivity but also
ALT levels and histological markers of NASH in overweight
subjects with non-alcoholic fatty liver.15 In vitro, PPAR-c
plays a significant role in the transcriptional activation of the
adiponectin gene.16 Therefore, the reported beneficial effect of
rosiglitazone in patients with NASH may be due in part to
the increasing effects of thiazolidinedione on adiponectin
expression.15 16
In conclusion, we have demonstrated significantly
decreased adiponectin and adipoRII expression in liver
biopsies of patients with NASH, suggesting that the funcï¿¾tional pathway of this important adipokine and its liver
specific receptor might be impaired in NASH.
ACKNOWLEDGEMENTS
This work was supported by grant P-15783-Med of the Austrian
Science Fund (FWF) to HT and by a grant from the Spanish
Ministerio de EducacioÂ´n y Ciencia, SAF.2001/0876 (FP).
Authorsâ€™ affiliations
.....................
S Kaser, C F Ebenbichler, J R Patsch, University Hospital Innsbruck,
Department of Medicine, Division of General Internal Medicine,
Innsbruck, Austria
A Moschen, A Kaser, H Tilg, University Hospital Innsbruck, Department
of Medicine, Division of Gastroenterology and Hepatology, Innsbruck,
Austria
A Cayon, J Crespo, F Pons-Romero, University Hospital Marques de
Valdecilla, School of Medicine, Institute of Digestive Diseases,
Santander, Spain
Conflict of interest: None declared.
REFERENCES
1 Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine
regulating glucose and lipid metabolism. Trends Endocrinol Metab
2002;13:84â€“9.
2 Steppan CM, Lazar MA. Resistin and obesity-associated insulin resistance.
Trends Endocrinol Metab 2002;13:18â€“23.
3 Pellme F, Smith U, Funahashi T, et al. Circulating adiponectin levels are
reduced in nonobese but insulin-resistant first-degree relatives of type 2
diabetic patients. Diabetes 2003;52:1182â€“6.
4 Tschritter O, Fritsche A, Thamer C, et al. Plasma adiponectin concentrations
predict insulin sensitivity of both glucose and lipid metabolism. Diabetes
2003;52:239â€“43.
5 Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of
30-kDa adipocyte complement-related protein increases fatty acid oxidation
in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A
2001;98:2005â€“10.
6 Berg AH, Combs TP, Du XL, et al. The adipocyte-secreted protein Acrp30
enhances hepatic insulin action. Nat Med 2001;7:947â€“53.
7 Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein,
adiponectin, suppresses lipid accumulation and class A scavenger receptor
expression in human monocyte-derived macrophages. Circulation
2001;103:1057â€“63.
8 Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the
family of soluble defense collagens, negatively regulates the growth of
myelomonocytic progenitors and the functions of macrophages. Blood
2002;96:1723â€“32.
120 Kaser, Moschen, Cayon, et al
www.gutjnl.com
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. 
. Technical Services Serials
at New York University, Serials Bobst Library on November 3, 2025 http://gut.bmj.com/ Downloaded from 10 December 2004. 10.1136/gut.2003.037010 on Gut: first published as 

9 Xu A, Wang Y, Keshaw H, et al. The fat-derived hormone adiponectin
alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest
2003;112:91â€“100.
10 Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that
mediate antidiabetic metabolic effects. Nature 2003;423:762â€“9.
11 Crespo J, Cayon A, Fernandez-Gil P, et al. Gene expression of tumor necrosis
factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis
patients. Hepatology 2001;34:1158â€“63.
12 Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment:
insulin resistance and beta-cell function from fasting plasma glucose and
insulin concentrations in man. Diabetologia 1985;28:412â€“19.
13 Debard C, Laville M, Berbe V, et al. Expression of key genes of fatty acid
oxidation, including adiponectin receptors, in skeletal muscle of type 2
diabetic patients. Diabetologia 2004;47:917â€“25.
14 Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis.
N Engl J Med 2000;343:1467â€“76.
15 Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved
nonalcoholic steatohepatitis after 48 weeks of treatment with the PPARï¿¾gamma ligand rosiglitazone. Hepatology 2003;38:1008â€“17.
16 Iwaki M, Matsuda M, Maeda N, et al. Induction of adiponectin, a fat-derived
antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes
2003;52:1655â€“63.
Clinical Evidenceâ€”Call for contributors
Clinical Evidence is a regularly updated evidence-based journal available worldwide both as
a paper version and on the internet. Clinical Evidence needs to recruit a number of new
contributors. Contributors are healthcare professionals or epidemiologists with experience in
evidence-based medicine and the ability to write in a concise and structured way.
Areas for which we are currently seeking authors:
N Child health: nocturnal enuresis
N Eye disorders: bacterial conjunctivitis
N Male health: prostate cancer (metastatic)
N Womenâ€™s health: pre-menstrual syndrome; pyelonephritis in non-pregnant women
However, we are always looking for others, so do not let this list discourage you.
Being a contributor involves:
N Selecting from a validated, screened search (performed by in-house Information
Specialists) epidemiologically sound studies for inclusion.
N Documenting your decisions about which studies to include on an inclusion and exclusion
form, which we keep on file.
N Writing the text to a highly structured template (about 1500â€“3000 words), using evidence
from the final studies chosen, within 8â€“10 weeks of receiving the literature search.
N Working with Clinical Evidence editors to ensure that the final text meets epidemiological
and style standards.
N Updating the text every six months using any new, sound evidence that becomes available.
The Clinical Evidence in-house team will conduct the searches for contributors; your task is
simply to filter out high quality studies and incorporate them in the existing text.
N To expand the topic to include a new question about once every 12â€“18 months.
If you would like to become a contributor for Clinical Evidence or require more information
about what this involves please send your contact details and a copy of your CV, clearly
stating the clinical area you are interested in, to Klara Brunnhuber (kbrunnhuber@
bmjgroup.com).
Call for peer reviewers
Clinical Evidence also needs to recruit a number of new peer reviewers specifically with an
interest in the clinical areas stated above, and also others related to general practice. Peer
reviewers are healthcare professionals or epidemiologists with experience in evidence-based
medicine. As a peer reviewer you would be asked for your views on the clinical relevance,
validity, and accessibility of specific topics within the journal, and their usefulness to the
intended audience (international generalists and healthcare professionals, possibly with
limited statistical knowledge). Topics are usually 1500â€“3000 words in length and we would
ask you to review between 2â€“5 topics per year. The peer review process takes place
throughout the year, and our turnaround time for each review is ideally 10â€“14 days.
If you are interested in becoming a peer reviewer for Clinical Evidence, please
complete the peer review questionnaire at www.clinicalevidence.com or contact Klara
Brunnhuber (kbrunnhuber@bmjgroup.com).
Adiponectin and its receptors in NASH 121
www.gutjnl.com
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. 
. Technical Services Serials
at New York University, Serials Bobst Library on November 3, 2025 http://gut.bmj.com/ Downloaded from 10 December 2004. 10.1136/gut.2003.037010 on Gut: first published as 

